[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346288-105":59,"doc-detail-346288-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","peli1-in-human-cancers-a-pan-cancer-exploration-of-its-molecular-function-clinical-significance-and-immunomodulatory-roles","PELI1 in human cancers - a pan-cancer exploration of its molecular function, clinical significance, and immunomodulatory roles","","Pan-cancer study characterizing PELI1 (Pellino1), an E3 ubiquitin ligase regulating inflammatory and immune responses, across human tumors. Bioinformatics analyses used R and multiple online platforms to assess abnormal expression, genetic alterations, prognostic/diagnostic relevance, and epigenetic regulation. Liver hepatocellular carcinoma (LIHC) findings were validated in vitro with LIHC cell lines, testing proliferation, apoptosis, cell cycle changes, and signaling pathway activity. Results show frequent PELI1 overexpression and poor prognosis, implicating epigenetic control and MAPK-ERK–linked immune modulation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/peli1-in-human-cancers-a-pan-cancer-exploration-of-its-molecular-function-clinical-significance-and-immunomodulatory-roles/346288/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/peli1-in-human-cancers-a-pan-cancer-exploration-of-its-molecular-function-clinical-significance-and-immunomodulatory-roles/346288.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of studying PELI1 across cancers?","Question",{"text":112,"@type":113},"To clarify PELI1’s pan-cancer biological significance, including its molecular functions, clinical relevance, and immunomodulatory roles.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which analyses were used to characterize PELI1 in tumors?",{"text":117,"@type":113},"The study combined R-based workflows with online bioinformatics tools to evaluate abnormal expression, genetic alterations, prognostic and diagnostic associations, and epigenetic regulation, then validated key findings in LIHC cell experiments.",{"name":119,"@type":110,"acceptedAnswer":120},"How does PELI1 affect liver hepatocellular carcinoma in functional experiments?",{"text":121,"@type":113},"In LIHC cell lines, PELI1 knockdown suppressed proliferation, promoted apoptosis, and induced G1-phase cell-cycle arrest, with effects linked to the MAPK-ERK pathway.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},346288,1790131227,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","TYPE Original Research PUBLISHED 05 January 2026  \nDOI 10.3389/fimmu.2025.1682086  \nOPEN ACCESS  \nEDITED BY  \nPengda Liu,  \nUniversity of North Carolina at Chapel Hill, United States  \nREVIEWED BY  \nWenjia Wang,  \nFirst Afﬁliated Hospital of Zhengzhou University, China  \nPei Shengbin,  \nChinese Academy of Medical Sciences and Peking Union Medical College, China  \n*CORRESPONDENCE  \nBing Chen  \n [chenbing2004@126.com](chenbing2004@126.com)[ ](chenbing2004@126.com)Xiaoqing Dong  \n [qgswns@126.com](qgswns@126.com)  \nRECEIVED 08 August 2025  \nREVISED 29 October 2025  \nACCEPTED 08 December 2025  \nPUBLISHED 05 January 2026  \nCITATION  \nXu Y, Zhou J, Chen X, Dong X and Chen B (2026) PELI1 in human cancers: a pan-cancer exploration of its molecular function, clinical signiﬁcance, and immunomodulatory roles. Front. Immunol. 16:1682086 .  \ndoi: 10.3389/fimmu.2025.1682086  \nCOPYRIGHT  \n© 2026 Xu, Zhou, Chen, Dong and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nPELI1 in human cancers: a pan-cancer exploration of its molecular function, clinical signiﬁcance, and immunomodulatory roles  \nYan Xu 1,2, Jiale Zhou 1, Xiaoran Chen 2, Xiaoqing Dong 1,2* and Bing Chen 1,2*  \n1 Department of Hematology, Nanjing Drum Tower Hospital, Afﬁliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China, 2 Department of Hematology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China  \nIntroduction: The E3 ubiquitin ligase Pellino1 (PELI1) is ubiquitously expressed inhuman tissues and primarily modulates inﬂammatory and immune responses; however, its pan-cancer biological signiﬁcance remains poorly characterized. Methods: We employed a combination of R software and online bioinformatics platforms—including UALCAN, HPA, GEPIA2, cBio Portal, STRING, TISIDB, SRAMP, LinkedOmics, and Sangerbox—to systematically characterize PELI1 inhuman tumors. Our analyses encompassed its abnormal expression, genetic alterations, prognostic and diagnostic relevance, and epigenetic regulation. Focusing on liver hepatocellular carcinoma (LIHC), we further explored the oncogenic functions of PELI1, its associated signaling pathways, and immunomodulatory roles. Key bioinformatic predictions were subsequently validated through in vitro experiments using LIHC cell lines, including functional assays (proliferation, apoptosis, and cell cycle) and signaling pathway analyses.  \nResults: PELI1 was frequently overexpressed across multiple tumor types and mainly correlated with poor patient prognosis. The highest frequency of PELI1 alterations was observed in patients with diffuse large B-cell lymphoma, primarily in the form of copy number ampliﬁcation, while R145Q/W represented the most recurrent mutation sites. PELI1 may drives cancer progression through epigenetic regulation involving DNA methylation and N6-methyladenosine (m6A) RNA modiﬁcations. PELI1 could potentially serve as a novel biomarker for diagnosing different cancer types. In LIHC speciﬁcally, PELI1 expression was signiﬁcantly elevated compared to adjacent non-tumor tissues. Functional studies revealed that PELI1 modulated cell apoptosis, cell cycle progression, immune responses and the MAPK-ERK pathway in LIHC. Furthermore, PELI1 may regulate immune checkpoints to inﬂuence the immune responses . PELI1 expression was positively correlated with the IC50 of hepatocellular carcinoma investigational drug–CFI-402257 . Experimental knockdown of PELI1 in LIHC cell lines suppressed proliferation, promoted apoptosis and induced G1-phase cell cycle arres","cbCainQrt0OmjaKM","https://ap.wps.com/l/cbCainQrt0OmjaKM","pdf",15669110,17,"English","# Introduction\n## Pan-cancer rationale and need for molecular targets\n# Methods\n## Bioinformatics pipeline and validation strategy\n# Results\n## PELI1 expression, alterations, prognosis, and biomarker value\n## LIHC functional effects and MAPK-ERK signaling\n## Immunomodulation and immune checkpoint regulation\n# Conclusions","[{\"question\":\"What is the main purpose of studying PELI1 across cancers?\",\"answer\":\"To clarify PELI1’s pan-cancer biological significance, including its molecular functions, clinical relevance, and immunomodulatory roles.\"},{\"question\":\"Which analyses were used to characterize PELI1 in tumors?\",\"answer\":\"The study combined R-based workflows with online bioinformatics tools to evaluate abnormal expression, genetic alterations, prognostic and diagnostic associations, and epigenetic regulation, then validated key findings in LIHC cell experiments.\"},{\"question\":\"How does PELI1 affect liver hepatocellular carcinoma in functional experiments?\",\"answer\":\"In LIHC cell lines, PELI1 knockdown suppressed proliferation, promoted apoptosis, and induced G1-phase cell-cycle arrest, with effects linked to the MAPK-ERK pathway.\"}]","PELI1 in human cancers - a pan-cancer exploration of its molecular function, clinical significance, and immunomodulatory roles | PDF",1790060799,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fc0e8261a1f9c604e40403dd5a3e29c4.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/438aaea93a6aaed154e45695d804f385.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c14f427d66c302bae631660f43d2c973.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/79f130858aee4b00b68606bed4698399.webp",980,1385]